Targeting the JAK2/STAT3 axis in Alzheimer's disease

Tomohiro Chiba, Marina Yamada, Sadakazu Aiso

Research output: Contribution to journalArticle

55 Citations (Scopus)


Background: Amyloid aβ (Aaβ) has long been implicated in the pathogenesis of Alzheimer's disease (AD). Little is known, however, about the intracellular events in neurons which lead to memory loss related to AD. Focusing on the fact that an AD-specific neuroprotective peptide named humanin (HN) inhibits AD-related neurotoxicity by activating the JAK2/STAT3 signaling axis, we recently found that age- and disease-dependent deterioration in the JAK2/STAT3 axis plays a critical role in the pathogenesis of AD. Objective/methods: Here we summarize the neuroprotective effect of HN and its derivative, named colivelin (CLN), and also review the roles of the JAK2/STAT3 axis in memory impairment related to AD. Results/conclusions: The JAK2/STAT3 axis is a major transducer of HN-mediated neuroprotective activity. Aâ-dependent inactivation of the JAK2/STAT3 axis in hippocampal neurons causes cholinergic dysfunction via pre- and post-synaptic mechanisms, which leads to memory impairment related to AD. This provides not only a novel pathological hallmark of AD but also a novel target in AD therapy.

Original languageEnglish
Pages (from-to)1155-1167
Number of pages13
JournalExpert Opinion on Therapeutic Targets
Issue number10
Publication statusPublished - 2009 Oct



  • Alzheimer's disease (AD)
  • Colivelin (CLN)
  • Humanin (HN)
  • Janus kinase 2 (JAK2)
  • Memory impairment
  • Neuroprotection
  • Signal transducer and activator of transcription 3 (STAT3)

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology
  • Clinical Biochemistry
  • Molecular Medicine

Cite this